-

Fresenius Kabi Introduces Copay Assistance for Cancer Treatments Using Generic Medicines

KabiConnect is designed to increase access and lower out-of-pocket costs for eligible patients with financial needs

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has introduced KabiConnect, part of the KabiCare patient support program in the United States, to offer copay assistance for the company’s generic oncology medicines. Fresenius Kabi offers the most comprehensive portfolio of generic injectable oncology medicines in the U.S.

KabiConnect offers eligible patients financial support covering more than 30 different oncology medicines. The program can lower out-of-pocket costs to as little as $0 a month for eligible patients. To determine eligibility, patients should speak to their physician. Enrollment is a simple online process. Details can be found on the KabiCare website at kabicare.us.

“The cancer journey through diagnosis and treatment can be complex for patients, families and caregivers,” said Tom Tsilipetros, senior director, Market Access, at Fresenius Kabi USA. “Our goal is help make this a little easier, and to make high-quality medicines more accessible and more affordable to more people. This kind of support can make a huge difference for patients and their families when they need it most.”

“As a leading U.S. developer and supplier of oncology injectable medicines, Fresenius Kabi knows firsthand the value generic medicines play in creating more affordable access to vitally important cancer treatments,” said Pere Berkowitz, vice president, Oncology Marketing, at Fresenius Kabi USA. “The introduction of the KabiConnect Copay Assistance Program extends our continuing commitment to support access to essential medicines for those patients with cancer.”

The copay assistance program is not available for patients who already receive reimbursement, in whole or in part, by any state or federal health care program.

About KabiCare, a Patient Support Program

Fresenius Kabi created KabiCare, a Patient Support Program, to support patient access to products across numerous therapeutic areas. KabiCare provides a patient-centric approach which includes support and resources for eligible patients, caregivers, and health care providers throughout the treatment journey. For eligible patients, support may include navigating complex insurance processes as well as financial assistance. For additional information, please call 1-833-KABICARE or visit kabicare.us.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in pharmaceuticals and medical technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.

Contacts

Matt Kuhn, (847) 550-5751
matt.kuhn@fresenius-kabi.com

Industry:

Fresenius Kabi

Release Versions
English

Contacts

Matt Kuhn, (847) 550-5751
matt.kuhn@fresenius-kabi.com

More News From Fresenius Kabi

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...

Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® 2 mg/1 mL due to a label mix-up. The MicroVault labeled as Morphine 2 mg/1 mL, may contain a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL. This recall is being conducted to the user level. Use of a MicroVault labeled as Morphine Sulfate Injection 2 mg/mL containing a prefilled syringe of Dilaudid (hydromorphone HCl) 0.5 mg/...

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan®* (rituximab).1 Under an exclusive commercialization agreement, Fresenius Kabi holds exclusive rights to commercialize the biosimilar in the United States. The product was developed, manufactured, and submitted for approval by Dr. Reddy's...
Back to Newsroom